| Current Assets: |
| Cash and cash equivalents |
160.07M |
| Marketable securities |
3.31M |
| Accounts receivable, net of allowance for doubtful accounts of $630 and $339, respectively |
39.43M |
| Inventories, net |
16.62M |
| Prepaid expenses and other current assets |
3.13M |
| Total current assets |
239.04M |
| Investments |
| Property and equipment, net |
2.23M |
| Intangible assets, net |
| Other assets |
9.37M |
| TOTAL ASSETS |
486.13M |
| Current Liabilities: |
| Accounts payable and other accrued obligations |
82.65M |
| Accrued compensation and related expenses |
3.72M |
| Deferred revenue |
3M |
| Common stock warrant liability |
| Accrued drug development costs |
13.28M |
| Total current liabilities |
103.45M |
| Capital lease obligations |
| Deferred revenue and other credits--less current portion |
3.46M |
| Zevalin related contingent obligations |
6.13M |
| Total liabilities |
201.75M |
| Commitments and contingencies |
0 |
| Stockholders' Equity: |
| Preferred stock value |
0 |
| Common stock, $0.001 par value--175,000,000 shares authorized; 52,947,221 and 51,459,284 issued and outstanding at June 30, 2011 and December 31, 2010, respectively |
60K |
| Additional paid-in capital |
465.37M |
| Accumulated other comprehensive loss |
931K |
| Accumulated deficit |
-182.11M |
| Total stockholders' equity |
284.38M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
486.13M |
| Series E convertible preferred stock |
| Stockholders' Equity: |
| Preferred stock value |
0 |
